celgene sent the stock creaming higher, there are so many shorts in that celgene name and they will feel it tonight. i'm not buying roots which is about a mile away from celgene. the fact that some rationality can prevail in a welcome sign that not everything is totally nuts, i like that, you ask the credit markets could be weakened if the energy companies go belly up, that's a reasonable assumption and there's also a possibility we will explore of later in the show that oil might be trading up because the dollar is getting weaker versus the eu euro. at least for the moment we have to accept the crazy town nature of stocks going higher because of a rebounding crude of a few pennies. when all but 7% of the underlying companies in the s&p see their earnings get hurt by than increase in energy costs. today ended up being a pretty darn good day when it should have been the exact opposite. then again when you're playing in an insane market and you can mimic it instantly why stand on the sidelines and see all the other nut jobs make all the money? >> brenda in california, brenda. >> caller: i

you can put a big multiple on celgene.le buying something up eight, but now the overhang is gone. bob hugen is an amazing manager. it bothers me tremendously that people had such little faith in celgene after all they had done for shareholders. does that take care of this risk of -- >> the challenge of -- >> yes. >> kyle bass will say nothing will take care of the risk. he will say he can challenge all these patents. bob hugen said that won't be an issue either. certain ceos, when they say it, they're not just making it out of whole cloth. he had tremendous conviction on this patent. the street did not, which is why you're seeing such a radical rerating of celgene. this is what happens when you have no patent cliff. stock to 130. 130 is where we fairly value the rest of the group. >> nike by far the best dow component today. takes the yearly gain to 41%, jim. no dow component has done better this year. >> nike coming in. the worries about china, china is their best. the worries about people spending more on sneakers in an

and gilead, to pete's point, is ridiculously inexpensive. >> but celgene trades at 20 times. if you are long on a name like this and you believe -- and i don't remember this argument, but whatever, dude. >> because you have so many arguments. >> another day and a number of arguments. >> and i think you guys would agree with this, celgene was 30 and went to 140 and now back at 120. it has held the trend line like a boss. it needs to held. as we go into next year, you don't want to see them breaking long-term trends. >> that would be down at 107. >> like a boss. >> the news came out, it was in the middle of the show, it must have been the dominator or someone broke the news. >> seaberg was here. >> i just said it needs to hold -- >> and dan said there is no way it holds on to that. >> i remember. i remember that. >> do not fill in the gap quickly. >> gilead, you like it and michael doesn't like it. he said it is a grinder next year. >> maybe it is a grinder. but i look at the name and the cash on the balance sheet and i think there is something. and we might disagree on one thi

the stock is back to where it was before the hideous quarter and then there's celgene. can you believe how many people have written off this stock? expected to earn $7.20 a year. meaning they sell at 17 times these 2017 numbers putting it at a discount to the average stocks and s&p 500. maybe that made sense when people were worried about the patent challenge and made that 720 cent figure stretch. it's not a joke. but all of that is over now that they made a deal now that gives them 7 more years of exclusivity on the recent drugs. now it's for real and the stock soared up $11 or 10% today and i don't think it's done. what could be the best to rebound? costco got the short end of the stick and the short reading which i dig because my charitable trust owns it tells me that any weakness can be explained away. the stock fell from 168 to 158. it starting to make a come back. i suspect it will clear the mid 160s in a very short period of time. quality retailers don't stay one more, this is a stock that sank from 109 down to 101 from what was supposed to be a bad miss. they ha

celgene will allow selling of generic revlimid.they'll make and market a generic pill starting in 2026. a year before it expires. the drug accounted for nearly 2-thirds of celgene's annual sales. german trade up by almost 6. >> now turring pharmaceuticals is moving on and launching the search for a new ceo. he re-signed on friday aisha daf ago arrested and charged with securities fraud. turring will also expand to include more independent directors and plans to cut an unspecified number of jobs as well. >> bed bath and beyond is slashing it's third quarter outlook citing sales. it now expects flat same store sales verses the previous estimate of growth of 1 to 3%. the company has seen softer in store transactions although online sales have been strong. bed bath and beyond falling 6% in after hours trade. off by a similar percentage in german trade. >> still to come here on worldwide exchange, donald trump continues to draw more criticism after spouting hateful comments against hillary clinton. what did the offender say this time? w

celgene shares are rallying. they will allow the u.s. an unlimited quantity of a generic drug as part of a patent settlement. they are a mia loma drug. shares up 9% after hours on this news. melissa. >> seema, thank you. >>> what does this mean for celgene? >> this is a great thing for them. the stock is up $10. overhang lifted. it is safe to buy the stock. >> for biotech. >> this stock has acted poorly. it was banging around whatever that level is, 110. if it fails tomorrow, you want to be out of the space altogether. >> it ain't failing, brother. >> i'll tune in tomorrow night. >> no, dan is going on vacation. >> he's checked out. >> tough day for chipolte on renewed worries of another e-coli outbreak. in the past three months the stock has fallen nearly 30% losing a third of its value. will it stunt the growth and make it a cheap stock. maybe not. take a look at several casual competitors. shake shack, mcdonald's at 20 times, yum at 20 times and jack at 19 times. >> we talked about this. this is really about putting your finger up in

thousands of investors executives and others head toe san francisco every january 11th to the 14th where celgene provide guidance for the year ahead. and finally, at the end of the month, an fda decision expected in hepatitis c merck may join gilead and abhave i with a new regimen north infection. michael yee says the fda's decision may have an impact as much as 5% on shares of gilead but price is a big question for these drugs. investors will be watching closely to see if merck offers a major discount to compete. investors hope the first month of the new year brings better news than the last six months of the old one. i'm meg terrell. >> did you ever wonder where all that money the movies make at the box office goes? we'll tell you who gets what and why it's so important. >> here's a look what to watch for on wednesday. housing once again grabs the headlines with two doo points. first with mortgage applications and then pending home sales for november. analysts are expecting a solid rise which is a good sign for housing activity. >>> and finally,ing with crude being a driver for stocks recently

also, celgene, the top performer on a percentage basis, and shares are up sharply after they sell therket is very bullish. one analyst says this is the best -- the biggest overhang on these celgene stock has now been lifted. maintains a price target that suggests the stock may move. keeps watchabigail on the nasdaq, we are keeping a list of who has been naughty and nice in the s&p 500. this tracks the s&p 500's biggest winners and losers. at the top of the list, netflix, so far this year, best-performing stock. a dramatic slump in oil prices. energy is the biggest loser. a loss of 77%. we want to focus on when resorts resorts. wynn look at netflix andwyn since they both target those who just want to have some fun. let's begin with netflix. that is easy one. they did supremely well. going to netflix more and more and watching their shows. how will that continue in 2016? chris: i remember at the start of this year, this was going to be the year of online tv. boy, we saw cbs and hbo and all of these other people launch. there does not seem to be anything stopping netflix right now. it's

celgene. how can we not go with quality? i'd like to go to joe in >> royal dutch shell. >> sell, sell, sell. they can't handle these oil prices. bill in california, billll >> i have frontier communications for the dividend and long-term investments. >> yeah but we don't want to reach. i'd rather see you in verizon or att. let's take one more. brian in jersey, brian >> nvidia, buy sell or hold? >> i have to b bst it. it's having a great quarter. and that, ladies and gentlemen, conclusion of the lightning round. sponsored by t.d. ameritrade. >> of all the -- will investors keep their fangs out? fang? except for of course i would have acknowledged that i coined fang. should have copyrighted it. fang. >> fangs.hma... ...one of many pieces in my life. so when my asthma symptoms kept coming back on my long-term control medicine, i i lked to my doctor anan found a missing piece in my asthma treatment. once-daily breo prevents asthma symptoms. breo is for adults with asthma not well controlled on a long-term asthma control medicine,

jpmorgan has an overweight rating and he says the biggest overhang on celgene stocks has been lifted. may move higher by 15% from current levels. another source of strength from the composite index and biotech is regeneron, shares up nicely today, perhaps for two reasons. less of uncertainty plaguing regeneron over the last six months. for the year, it's up more than 30%. back to you. i saw a lot of movers in oil today. you got some down there? is the topl, energy mover at the nasdaq today. we have not queued in on any of these names in particular. we been focusing on health care and apple. matt: we are showing a string of nymex crude. it was a 4% yesterday as well because of the contract switchover. gain this week, pretty darn good. 3473,ked off the week at i believe. that helps the oil sector. it hurts when the price of oil rises. it hit delta and united a little bit hard. abigail: that is true. american airlines, jetblue both down. analysts who were saying that the possibility of lower oil into 2016 good help these companies, that would depend on whether or not oil continues down p

i saw biogene and celgene within a few minutes of trading this morning, thanks to bob wang for pointing them out to me. then i saw some of the old buying drug companies rally along with the big biotechs. there have been some nasty pressures on netflix and amazon. many people were incredit will you say. then higher growth semi-conductors gained. google reversed. yahoo! has decided not to spin off its alibaba stake, something that led to a gain in yahoo!. perhaps that can be built on tomorrow. now i think that the entire move in high growth is always going to be -- if oil goes down, it's going to wipe that group out again. oil managed to rally back into a flat line, that's a buck decline and then back. but after the close, kinder morgan, kmi, announced a devastating dividend cut from 51 cents to 12.five cents per share. bond whisperers, people in the credit market, told me it would be about a 50% cut. that's more. who knows if that whole group, which was momentarily on the mend, gives it up again? and a lot of wealthy investors own those. that stock is getting crushed after hours on top o

if you like bristol-meyers at 30 times forward earnings, you've got to love celgene at $20 and amgen at $16. meg, thank you. >>> federal and local security officials are beefing up security across the board. nbc news reporter sara dallof is in the center there. >> the threat picture changed over the past one to two years because of isis and events across the world in the past few months. because of that, they have beefed up security here at times square. 6,000 police officers assigned here to patrol the streets, patrol the water, patrol the air. some of these officers are going to be carrying long guns. that is a first for new year's eve celebrations. in addition to that, you are going to have bomb-sniffing dogs and chemical and radiation detectors. that is all in hopes of keeping the 1 million people expected to crowd into times square to watch the ball drop off to a safe and a fun new year's eve. as for the ball, it got a bit of a facelift this year. 200 new crystals added to it. we've been listening to sound checks from various performers. a really star-studded evening. all leadin

stock one, celgene. big move today after settling patent litigation.tive analyst comments out there. cowan saying very favorable outcome. it remains one of their top large cap biocap picks. their target is $150. that's still about 20% upside and j & p adding this quote, it removed a big investment overhang. >> a bigger investment overhang is 2016, an election year, and drug pricing will be a key issue and that's been dogging the entire sector since august. we'll see how this resolves itself, if at all, going into next year. second stock we're watching micron technology. earnings miss on q1 sales and guided lower. raymond joins downgrading it. near-term conditions seem more broadly weaker meaning it's not just weakness in the pc segment pment memosegment. stock sort of in the middle there. >> and the cash burn here also a big concern for micron tech. it's been a disappointing couple months. i guess i have to remind people this was an under $2 stock back in 2008. what a volatile name this has been. let's move to stock number three and that is finish line

. >> celgene reaching an agreement over the blood transfusion. >> short-term investors hate uncertaintyforward to the next year. you're going to see hillary talking a lot. i think that's going to take down the confidence. their lead drug costs over $100,000 a year, and when you start getting that chatter, it's going to be hard for that stock to move up. indicated that commodity producers are likely to reduce a production next year. >> it's what they should be doing. all the names are rallying as they've gotten. futures expiration. got the selling out of the way. gives them a chance. >> okay. five trading days left in this year. we check in on the halftime portfolio challenge coming up. dr. jay is making some moves there. selling three stocks today. stay tuned for those trades coming up next. our own jon najarian headed to the mall of america to get gifts for our traders. take a look. >> so i had to get stephen weiss something, and he's a guy on the go, and he's always running out of juice on his phone, so i had to get him a phone charger, and because it's stephen weiss, it had to be in

. >> celgene. clearly it becomes patented but ours is half and half so it's two big businesses with competing strategic visions so if we split those up would we unlock value? >> what's the answer right now? >> don't know. >> what will determine the answer? what will you be looking senate. >> well, we're creating separate operating units, giving them as much autonomy as we can inside pfizer. we're giving enough information to the street so they can calculate pro forma pnls. we'll start giving them balance sheets and at the end of '16 latest is when i have the ability to do a transaction if i wanted to, i need three years of financials, we'll look at the company and say do we believe these two divisions are working for pfizer or not? could they work better outside, is there trap value? i.e. if we look at their pes or what their pe should be or their earnings does that give me a higher value of shares and can we sufficiently realize that value. >> there's a saying on wall street that nothing happens f

shares of celgene getting a boost. the company settling patent litigation in the u.s. for its top seller. it will allow for the sale of the generic version of the drug more than a year before the patents actually covering the drug will expire. speaking of beatles. >> yes, sir. >> sir paul was at the rangers game on sunday night. >> was he really? >> yeah. so it's just really cool what they do. all of a sudden they'll start playing on the big screen, i think they did like, i don't know some great song. >> i'll hold your hand. >> and you saw john like this and paul like that and then they focus in on him and he waves and he's smiling and holding a rangers puck so i was on one side. i could see the camera so i picked him out where he was across from us and then i watched him the rest of the game. >> you watched him instead of the game. >> but i was watching how long he stayed. who he was with and how much fun he was having. they played a lot of beatles songs and he sings along. >> that's what i want to hear. >> he's into being paul. i didn't see him eating any of those ho

if you look at the numbers in that index, you see celgene or alexi on putting up strong points. there are big stories of winners today, it is not all about the losers. $36.64 as the low. you were close. were oh, i thought you telling me the correlation between the oil and the s&p 500. >> that would be awesome. >> checking in now, mark crumpton. john kerry says that he has confirmed with the united secretary on the state of global climate change talks. is there to create an agreement by the end of next week. -- is reviewing the visa program which allowed one of the california shooters into the united states. admittedmalik was one into the country last year to a mary -- to marry an american citizen. it is among the smallest visa categories managed. they typically focus on marriage fraud. oscar pistorius is now free on bail. he will remain on house arrest until appealing his murder conviction for killing his girlfriend, reeva steenkamp. south africa's supreme court overturned the lesser charge of manslaughter. healthns who don't buy insurance would be able to avoid the penalty next

the big four, amgen, celgene, biogen and gilead, all doing fairly well except biogen, down due to a slowdownf its multiple sclerosis drugs. a lot of catalysts coming ahead for biogen. the second half so rocky for the index. investors saying they're exhausted. looking looking ahead to january, there should be a lot of catalysts. >> it's been one of the futures of the bull market, biotech and healthcare is a place investors look to in a slow-growth year what are they saying? can that continue into 2016? >> for biotechs specifically, they're not certain it will have another year of outperformance. in january of last year we asked every ceo whether they thought biotech would outperform again. they all said yes for 2015. going into 2016 on, it sounds like the sentiment has changed. it doesn't sound like you can expect it to youtperform the broader market. >>> winter weather wreaking havoc on travel. thousand of flights being canceled or delayed today. and oil rebounding today after a big fall yesterday. find out what it means for energy stocks which are strong right now. wti crude up almost 2.5%.

biotech stocks as a part of healthcare helping the sector higher with names like celgene and biogen. it's the third best performing sector on that basis. t the ibb up about a percent or so on this down day as well. at least for right now, biotech showing relative strength. back over to you. >>> thank you very much. let's get over to cme group and rick santelli with the santelli exchange in chicago. good morning. >> good morning. it's all about manufacturing. we have all become very much focused on that sector even given the fact that it's 12% of gdp because it's the canary in the coal mine, so to speak. to that i would like to welcome my guest today, chad nutrey, head economist from the national association of manufacturers. welcome. >> thanks. >> your most recent read, i'm feeling fortunate it is early. 59.6. these are quarterlies. it's not a finalized read. compared to previous quarters, this is the lowest level since q4q dominguq4 2012. >> 91% of our members were positive in december of last year, so we've seen sentiment fall dramatically over the course of the last 12 months. tho

producers of the commodity, gets scary, not to mention they were take out other names, too, biotech, celgene it was let off to this macro trade, being short the euro, long euro stocks and long some of the bonds, all of which came back to haunt them and the dollar reversing course dramatically when draghi didn't do as much as people thought. it bled into the broader market. >> when people are wrong they pull back. >> they pull back. >> the people we're talking about are not trying to figure out if they want to buy merck versus pfizer. though made giant bets. the cogoldman sachs bet that th will go through the roof. wrong bet. draghi saying things so that we get more negative. didn't help. some give up. others thought the employment number wouldn't be too hot. they take names in biotech. there was a series of manufacturing dated a that was horrendous. >> ism earlier in the week. >> terrible rail, truck numbers. truck numbers are recession. just recession. the number of truck builds. cutting back construction is not bad in this employment number. that was good. the final thing is this pipeline

companies like celgene and illumina often have big news and guidance there as well.t the end of the on, january 28th merck is expected to have an fda decision on it's hepatitis c combo. rbc capital markets estimates that this decision for merck's drug to have a 5% stock impact on gilead. what's going to be important to watch there of course we all know hepatitis c price is a big issue. they need to give a business dig count in order to get market share in this competitive space. >> mike, your take? >> it's been amazing to me you go through these periods where biotech trades as one block, despite the fact that all these different companies with different pros dekts that are red or green. are we in a mode where there's general skepticism toward each of these companies, toward the business model toward pricing? >> there's general skepticism across the industry but individual companies people feel differently about. it has been interesting to see the sentiment shift from, for example, there was a company zak jen, canceled out of conferences, normally in the beginning of

biotech has been bucking the trepd today, the ibb was up 2% a little while ago, just below that level, celgene is up 2.6% and biogen is up 2.5% today among the high flyers, if you will, in that sector. >> speaking of high flyers julia boorstin is attending the business insider conference. they bring together big names in media and tech. >> she joins us with venture capital's jim breyer. >> thanks so much. jim, thanks for joining us today. >> thank you for having me back. >> you are a legendary investor, early investor in facebook but you are here at the conference to speak with the ceo of legendary the film studio. why did you decide to invest in legendary i know you also sit on the board. why legendary as opposed to another media company? >> i had invented and joined the board of marvel entertainment in 2006 and i always had a passion for intellectual property, i was a comic book geek as well i should say but intellectual property as applied to a number of different distribution mechanisms, the internet as well as live theatrical and heat al cal. when i met thomas he reminded me so much of a

across the board and it really doesn't matter whether you're looking at stuff that's biotechy like celgene or even hmos and other style stocks in that group like aetna and universal health care and some of the hospitals like tenet health care are also to the downside. remember, melissa, the last great trade that was out there was stay long the dollar and stay short the euro. that was one of the last crowded trades that are out there, and now that's kind of gone, so that's another thing that's not working for the trading community this year. and biotech was another one. that's generally been working fairly well. it's had some ups and downs and even today you can see that trade also not working. i guess what i'm saying is a lot of trades that are out there, long trades, are not working very well. this long dollar short the euro is one of the last ones that were out there is now everybody, brian, everybody has had a crummy year as a result of the fact that none of the long trades have been working very well. >> let's get back into the news of the day outside of the markets and the markets tog

celgene named a top biotech pick. >>> look at three of the largest u.s. airlines.ta and united are down by double digits. the airline that's soaring in the stock market, jetblue up 45%. southwest and spirit airlines are getting whacked. they're down about 45%. the three major carriers have usually shrugged off low-cost carrier competition but after rapid expansion, they are responding aggressively. one study showing that overall airfares for december are down as much as 24% this year. that's some pretty good news. seth kaplan is managing partner of airline weekly. seth, listen, our viewers and listeners know what they're paying for gasoline for their cars. i've got to imagine that the airlines are just as happy about their prices at their pump, so to speak. are we going to see ticket prices continue to fall because of low air fuel costs? >> yeah. now, the declines will probably slow down somewhat, brian. this year we've seen them really tumble, and the airlines are trying to get their hands around that because they realize at some point, you know, that's going to f

celgene, anat interesting drugmaker that had been in a fight with matt: over one of its drugs.ttle that fight and not go so that matt: -- 2022 -- and a lot of retailers are having a tough time going into this holiday season. 6.25%th & beyond is down because the company released limitary figures below its estimate in terms of profit, same-store sales and earnings. bed bath & beyond said their same-store sales were down 2/10 of a percent because brick-and-mortar shops, internet sales are up 25%. -- nikeout yesterday -- china revenue in the quarter of 24%, almost $1 billion. this company is firing on all cylinders but it is the shoes. i was quoting mars blackmon when he said it has to be the shoes. the shoes make up the lion share of their property -- profits. stephanie: it is the margin on those shoes. jordans, the golden state warriors question, it is the number one issue out there. shoes?ho makes those who puts those shoes together? operate the machines to build the shoes in malaysia? stephanie: third-party factories. matt: i'm wondering what kind of people are making those sho

last year i visited celgene corporation in new jersey to learn of their extraordinary efforts to used blood to heal diabetic foot ulcers and how they turn embryotic membrane to help wounds to the approval and regulatory -- to finalization. again, i want to thank the chief co-sponsor, ms. matsui, mr. jolly and mr. fattah. again, this is a bipartisan bill and i ask unanimous consent to revise and extend my remarks and, again, i want to thank the chairman for your leadership. the speaker pro tempore: without objection. the gentleman from pennsylvania is recognized. mr. pitts: i yield back the balance of my time. the speaker pro tempore: the question is will the house suspend the rules and concur in the senate amendment to h.r. 2820. those in favor say aye. those opposed, no. mr. pitts: mr. speaker, i request the yeas and nays. the speaker pro tempore: the yeas and nays are requested. all those in favor of taking this vote by the yeas and nays will rise and remain standing until counted. a sufficient number having arisen, the yeas and nays are ordered. pursuant to clause 8 of rule 20, fu